Publications by authors named "Cassandra Key"

Claim this Profile
S
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Long-Acting FGF21 Analog Zalfermin.
Kirsten Dahl, Martin Haljeta Friedrichsen, Rasmus Ribel-Madsen, Jakob Schiøler Hansen, Jesper Ole Clausen, Cassandra Key

Clin Transl Sci· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial.
Agnes Gasiorek, Arne Heydorn, Sanaz Gabery, Julie B Hjerpsted, Katrine Kirkeby, Cassandra Key

Lancet· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.
Kirsten Dahl, Søren Toubro, Sohan Dey, Ruben Duque do Vale, Anne Flint, Cassandra Key

Lancet· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 Studies to Assess Inhaled Seralutinib as a Perpetrator or a Victim of Drug-Drug Interactions in Healthy Participants.
Jianke Li, Ed Parsley, Matt Cravets, Emanuel DeNoia, Cassandra Key

Clin Pharmacol Drug Dev· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I randomized, double-blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects.
Kenan Gu, Dennis Ruff, Cassandra Key, Marissa Thompson, Shoshanna Jiang

Clin Transl Sci· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis